[go: up one dir, main page]

LT2790721T - Neacilinto grelino fragmentai, skirti naudoti preiderio-vilio sindromo gydymui - Google Patents

Neacilinto grelino fragmentai, skirti naudoti preiderio-vilio sindromo gydymui

Info

Publication number
LT2790721T
LT2790721T LTEP12829142.4T LT12829142T LT2790721T LT 2790721 T LT2790721 T LT 2790721T LT 12829142 T LT12829142 T LT 12829142T LT 2790721 T LT2790721 T LT 2790721T
Authority
LT
Lithuania
Prior art keywords
prader
fragments
treatment
willi syndrome
unacylated ghrelin
Prior art date
Application number
LTEP12829142.4T
Other languages
English (en)
Inventor
Aart Jan Van Der Lely
Thierry Abribat
Original Assignee
Millendo Therapeutics Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millendo Therapeutics Sas filed Critical Millendo Therapeutics Sas
Publication of LT2790721T publication Critical patent/LT2790721T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/62Insulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
LTEP12829142.4T 2011-12-15 2012-12-14 Neacilinto grelino fragmentai, skirti naudoti preiderio-vilio sindromo gydymui LT2790721T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576217P 2011-12-15 2011-12-15
PCT/IB2012/002867 WO2013088241A1 (en) 2011-12-15 2012-12-14 Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin

Publications (1)

Publication Number Publication Date
LT2790721T true LT2790721T (lt) 2019-02-11

Family

ID=47780096

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12829142.4T LT2790721T (lt) 2011-12-15 2012-12-14 Neacilinto grelino fragmentai, skirti naudoti preiderio-vilio sindromo gydymui

Country Status (16)

Country Link
US (2) US9550821B2 (lt)
EP (1) EP2790721B8 (lt)
JP (1) JP6031121B2 (lt)
CA (1) CA2857276A1 (lt)
CY (1) CY1121296T1 (lt)
DK (1) DK2790721T3 (lt)
ES (1) ES2705499T3 (lt)
HR (1) HRP20190062T1 (lt)
HU (1) HUE042102T2 (lt)
LT (1) LT2790721T (lt)
PL (1) PL2790721T3 (lt)
PT (1) PT2790721T (lt)
RS (1) RS58237B1 (lt)
SI (1) SI2790721T1 (lt)
TR (1) TR201900438T4 (lt)
WO (1) WO2013088241A1 (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2790721B8 (en) 2011-12-15 2018-11-28 Millendo Therapeutics SAS Fragments of unacylated ghrelin for use in the treatment of prader-willi syndrome
US20140378380A1 (en) 2013-06-21 2014-12-25 Alizé Pharma SAS Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
WO2016044467A1 (en) * 2014-09-17 2016-03-24 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
CA3125835C (en) * 2014-11-14 2023-01-03 Neil M. Cowen Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
US10053693B2 (en) 2016-01-19 2018-08-21 Mubin I. Syed Method for controlling obesity using minimally invasive means

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US6627729B1 (en) 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
WO2001087335A2 (en) 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
CA2411667A1 (en) 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
WO2002060472A1 (fr) 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedes pour des etats d'hyponutrition
WO2002060477A1 (en) 2001-01-31 2002-08-08 Human Genome Sciences, Inc. Scaffolded fusion polypeptides, compositions for making the same and methods of using the same
EP1455814B1 (en) 2001-12-18 2012-04-04 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin for use in the treatment of insulin resistance
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US7666833B2 (en) * 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
CA2471879C (en) 2002-05-21 2014-02-25 Daiichi Suntory Pharma Co., Ltd. Pharmaceutical composition containing ghrelin
CA2543507C (en) 2003-10-24 2012-05-01 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
EP1812044A2 (en) 2004-10-27 2007-08-01 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
US8653022B2 (en) 2006-03-28 2014-02-18 Liat Mintz Use of ghrelin splice variant for treating hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or coronary heart disease and/or weight management and/or diabetes and/or hyperglycemia
US8318664B2 (en) * 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
EP2152297B1 (en) 2007-05-31 2015-04-29 Alizé Pharma SAS Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
EP2067481A1 (en) * 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin
US8476408B2 (en) * 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
EP2790721B8 (en) 2011-12-15 2018-11-28 Millendo Therapeutics SAS Fragments of unacylated ghrelin for use in the treatment of prader-willi syndrome

Also Published As

Publication number Publication date
TR201900438T4 (tr) 2019-02-21
WO2013088241A1 (en) 2013-06-20
HUE042102T2 (hu) 2019-06-28
JP6031121B2 (ja) 2016-11-24
ES2705499T3 (es) 2019-03-25
PT2790721T (pt) 2019-01-24
US9550821B2 (en) 2017-01-24
JP2015501832A (ja) 2015-01-19
US20140336109A1 (en) 2014-11-13
HRP20190062T1 (hr) 2019-03-08
PL2790721T3 (pl) 2019-05-31
RS58237B1 (sr) 2019-03-29
EP2790721A1 (en) 2014-10-22
CY1121296T1 (el) 2020-05-29
DK2790721T3 (en) 2019-02-04
EP2790721B1 (en) 2018-10-17
CA2857276A1 (en) 2013-06-20
SI2790721T1 (sl) 2019-03-29
EP2790721B8 (en) 2018-11-28
US20130157936A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
IL240898A0 (en) Antibodies against a5c and methods of using the antibodies
EP2788075A4 (en) DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT
IL231836A0 (en) The vehicle for treating the siege
EP2720625A4 (en) DEVICES FOR THE TREATMENT OF FISTLES AND CORRESPONDING METHODS
PL2526141T3 (pl) Sposób obróbki powierzchniowej
IL220594A0 (en) Treatment method
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
SI2790721T1 (sl) Fragmenti neaciliranega grelina za uporabo pri zdravljenju Prader-Willijevega sindroma
IL235272B (en) Alfentanil preparation for the treatment of acute pain
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB201105523D0 (en) Treatment method
IL230746A0 (en) 2-aldh inhibitors in the treatment of addiction
IL229438A0 (en) Methods for treating obesity and/or metabolic syndrome
PL2734634T3 (pl) Igf-1 do zastosowania do leczenia migreny
PH12014501052A1 (en) Methods and compositions for the treatment of diabetes and related symptoms
ZA201206361B (en) Method and composition for the treatment of a surface
PL2588093T3 (pl) Tapentadol do zastosowania w leczeniu zespołu jelita drażliwego
GB201107553D0 (en) Composition and methods for the treatment of neuroendocrine and pitutitary tumoars
IL230474B (en) Lactoferrin segments and their uses
HK1189818A (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
GB201102232D0 (en) Inventions and therapy
GB201102234D0 (en) Inventions and therapy
GB201102212D0 (en) Inventions and therapy
GB201102239D0 (en) Inventions and therapy
GB201102210D0 (en) Inventions and therapy